Celyad Oncology SA
Common Stock · EUR · F
Price
€0.258
Cap
€3.21M
Earnings
—
30d Trend
-6.2%
176% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 42×Macro 0.99 (−1%)=42
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
6-9 month opportunity — emerging trend
BRAIN47'S ASSESSMENT
I rate Celyad Oncology SA at 42/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is quality at 90/100. I classify this as a speculative position with the strongest thesis on a medium-term horizon.
PAST PERFORMANCE
1 MONTH
-6.9%
3 MONTHS
-25.0%
12 MONTHS
-35.8%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
6-9 month opportunity — emerging trend. Quality (90) and Technical (54) are the primary strengths. I note that fundamentals is the weakest area at 15/100 — this warrants monitoring. Historical volatility is elevated at 176%. I classify this as a speculative position — elevated volatility at 176% and smaller market cap define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.